Author:
Hou Wanting,Yang Biao,Zhu Hong
Abstract
Immunotherapy has dramatically changed prognosis for patients with malignant tumors. However, as a non-immunogenic tumor, pancreatic ductal adenocarcinoma (PDAC) has a low response to immunotherapy. Factors that contribute to the inefficiency of PDAC immunotherapy include the tumor microenvironment (TME) and its dense stroma, which acts as a barrier for drug delivery and immune cell infiltration. Recent studies have shown that nanoparticle-based therapeutic strategies have more promising applications in improving drug delivery and reversing the immunosuppressive TME for PDAC. Therefore, nanomaterial-based therapeutic approaches are expected to enhance the effectiveness of immunotherapy and improve prognosis of patients with PDAC. Here, we outline the status and dilemma of PDAC immunotherapy, and summarize the latest advances in nanoparticle-based treatment strategies to enhance the efficacy of PDAC immunotherapy.
Reference147 articles.
1. Pancreatic cancer;Lancet,2020
2. Pancreatic Cancer: A Review;JAMA,2021
3. Therapeutic developments in pancreatic cancer: Current and future perspectives;Nat. Rev. Gastroenterol. Hepatol.,2018
4. Chakrabarti, S., Kamgar, M., and Mahipal, A. (2022). Systemic Therapy of Metastatic Pancreatic Adenocarcinoma: Current Status, Challenges, and Opportunities. Cancers, 14.
5. Immunotherapy for pancreatic cancer: A 2020 update;Cancer Treat. Rev.,2020
Cited by
5 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献